Yaman A.S. Yousef

Yaman A.S. Yousef

Auto-generated profile, based on publicly available information

Yaman A.S. Yousef

Faculty of Medicine, Elrazi University, Khartoum, Sudan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2023 in Plastic Surgery
Verified
Journal Article
Closed access
AKAbdulrhman Khaity
Abdulrhman Khaity
KAKhaled Albakri
Khaled Albakri
NANada Mostafa Al-Dardery
Nada Mostafa Al-Dardery
YYYaman A.S. Yousef
Yaman A.S. Yousef
JFJose Antonio Foppiani
Jose Antonio Foppiani
SLSamuel J. Lin
Samuel J. Lin
Introduction: Hypertrophic and keloid scars are abnormal tissue growth that can be disfiguring, for which the available treatment has not yielded consistent results. Therefore, this study aimed to evaluate the capability of Adipose tissue-derived stem cell (ADSC) therapy in treating these scars. Methods: A literature search was conducted on PubMed, Scopus, Cochrane Library, and Web of Science from inception until July 2022. We included experimental studies that evaluated ADSCs as a therapy for hypertrophic and keloid scars in both in-vivo and in-vitro models. Results: Our findings extracted from 12 included studies demonstrated that ADSCs have a promising potential in reducing collagen deposition, proliferation, and migration rates of fibroblast, decreasing gene/protein expression of scar-related molecules including levels of TGF-β1 and lowering intracellular signal pathway-related molecules of hypertrophic and keloid scars in both models. However, no significant difference ( P > .05) was found in the hypertrophic scar in-vitro models in terms of DCN gene expression. Conclusion: Ultimately, the current studies included in this systematic review support the use of ADSCs to alleviate hypertrophic and keloid scars.